Diligence memo · auto-generated · as of July 3, 2026

Cero Therapeutics Holdings, Inc.

Cero Therapeutics Holdings, Inc. looks fair against its niche peers and is active on financing cadence.

SourceRaising on rhythm with a 4.0× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Cero Therapeutics Holdings, Inc. operates in Pharmaceuticals, based in SOUTH SAN FRANCISCO.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Cero Therapeutics Holdings, Inc. has raised $16M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $10M on 2024-02-14.

Most recent recorded round closed around 2025-04-22.

Valuation (modeled)modeled

Provath models Cero Therapeutics Holdings, Inc. at approximately $18M (range $5.7M–$32M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.11× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era. Within the normal band (111% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 7 months.

Last raise 14 mo ago; this sector typically re-raises about every 13 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 4.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 63% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 26% of those peers.

Closest niche peers: Incannex Healthcare Inc., Retension Pharmaceuticals, Inc., Eikonoklastes Therapeutics, Inc., Phoenicis Therapeutics, Inc., Pharmaceutical Resource Technology, Inc..

Peoplefiled

16 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.